Recursion Pharmaceuticals Inc (RXRX)
9.42
-0.09
(-0.95%)
USD |
NASDAQ |
May 17, 16:00
9.42
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Revenue (TTM): 45.23M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 45.23M |
| December 31, 2023 | 43.88M |
| September 30, 2023 | 46.93M |
| June 30, 2023 | 49.88M |
| March 31, 2023 | 46.52M |
| December 31, 2022 | 39.68M |
| Date | Value |
|---|---|
| September 30, 2022 | 28.50M |
| June 30, 2022 | 17.95M |
| March 31, 2022 | 12.80M |
| December 31, 2021 | 10.00M |
| September 30, 2021 | 10.05M |
| June 30, 2021 | 8.413M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
8.413M
Minimum
Jun 2021
49.88M
Maximum
Jun 2023
29.99M
Average
34.09M
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 35.93B |
| Absci Corp | 5.347M |
| Palatin Technologies Inc | 7.098M |
| Oragenics Inc | -- |
| Actinium Pharmaceuticals Inc | -- |